{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T03:34:52Z","timestamp":1784604892191,"version":"3.55.0"},"reference-count":27,"publisher":"Wiley","issue":"16","license":[{"start":{"date-parts":[[2013,5,14]],"date-time":"2013-05-14T00:00:00Z","timestamp":1368489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2013,8,15]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>This study sought to determine the feasibility and recommended phase 2 dose (RP2D) of the combination of cetuximab with chemoradiotherapy based on 5\u2010fluorouracil (5\u2010FU) and cisplatin (CP) in locally advanced anal canal carcinoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Cetuximab was administered on days 1, 8, 15, 29, 36, 43, and 50 (400 mg\/m<jats:sup>2<\/jats:sup> initial dose, then 250 mg\/m<jats:sup>2<\/jats:sup>\/week) concurrent with total dose radiation of 55 to 59 Gy, both starting on day 1. Escalating doses of 5\u2010FU (96\u2010hour infusion) and CP (2\u2010hour infusion), both on days 1 and 29, were administered according to the following design: starting dose level (0) 5\u2010FU\/CP\u2009=\u2009800\/60 mg\/m<jats:sup>2<\/jats:sup>\/day and up to dose level (+2) 5\u2010FU\/CP\u2009=\u20091000\/80 mg\/m<jats:sup>2<\/jats:sup>\/day.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Dose\u2010limiting toxicity (DLT) events (uncontrolled diarrhea or febrile neutropenia) occurred in 3 of 14 assessable patients receiving escalated dose of 5\u2010FU\/CP, with 1 in dose level (0) and 2 in dose level (+2). The RP2D was 5\u2010FU\/CP\u2009=\u2009800\/80 mg\/m<jats:sup>2<\/jats:sup>\/day. Because of unexpected non\u2010DLT treatment\u2010related grade 3 (G3) adverse events (AEs) such as thrombosis\/embolism, syncope, and infection occurring in\u2009\u2265\u200920% of patients, a safety expansion cohort with an additional 9 patients was investigated with the RP2D. The most frequent G3\/G4 AEs evaluated in 23 patients were radiation dermatitis (12 patients), diarrhea (10 patients), thrombosis\/embolism (6 patients), and infection (5 patients). The study was closed due to these severe AEs, although no G5 AEs occurred. Twenty of 21 patients (95%) achieved pathological complete response at primary tumor. With a median follow\u2010up of 43.4 months, the 3\u2010year locoregional control rate was 64.2%.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Cetuximab could not be integrated with chemoradiotherapy\u2010cisplatin\u2013based therapy due to the high toxicity rate. However, efficacy is encouraging and further investigation of an epidermal growth factor receptor\u2013targeted agent (other than cetuximab) concurrent with chemoradiation should be pursued. <jats:bold><jats:italic>Cancer<\/jats:italic> 2013;119:2973\u20142980<\/jats:bold>. \u00a9 <jats:italic>2013 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.28045","type":"journal-article","created":{"date-parts":[[2013,5,14]],"date-time":"2013-05-14T11:20:43Z","timestamp":1368530443000},"page":"2973-2980","source":"Crossref","is-referenced-by-count":57,"title":["Phase 1 study of cetuximab in combination with 5\u2010fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma"],"prefix":"10.1002","volume":"119","author":[{"given":"Luis O.","family":"Olivatto","sequence":"first","affiliation":[{"name":"Division of Clinical Oncology Hospital do Instituto Nacional de C\u00e2ncer Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando M.","family":"Vieira","sequence":"additional","affiliation":[{"name":"Coordination of Clinical Research Research Coordination Instituto Nacional de C\u00e2ncer Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno V.","family":"Pereira","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology Hospital do Instituto Nacional de C\u00e2ncer Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana P.","family":"Victorino","sequence":"additional","affiliation":[{"name":"Coordination of Clinical Research Research Coordination Instituto Nacional de C\u00e2ncer Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Bezerra","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology Hospital do Instituto Nacional de C\u00e2ncer Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos M.","family":"Araujo","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology Hospital do Instituto Nacional de C\u00e2ncer Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Erlich","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology Hospital do Instituto Nacional de C\u00e2ncer Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Faroni","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology Hospital do Instituto Nacional de C\u00e2ncer Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonaldson","family":"Castro","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology Hospital do C\u00e2ncer, Instituto Nacional de C\u00e2ncer Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward C.","family":"Lusis","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology Hospital do C\u00e2ncer, Instituto Nacional de C\u00e2ncer Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Marins","sequence":"additional","affiliation":[{"name":"Coordination of Clinical Research Research Coordination Instituto Nacional de C\u00e2ncer Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Gil","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Coordination of Clinical Research Research Coordination Instituto Nacional de C\u00e2ncer Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,5,14]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.16.1914"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.4837"},{"issue":"15","key":"e_1_2_7_4_1","article-title":"The pattern and timing of disease recurrence in squamous cancer of the anus: Mature results from the NCRI ACT II trial [Abstract]","volume":"30","author":"Sebag\u2010Montefiore D","year":"2012","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.1.70"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.479"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204082"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.4.904"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.13.3234"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60569-9"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805019"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70311-0"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.6857"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3656-4"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.11.057"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1090-x"},{"issue":"15","key":"e_1_2_7_17_1","article-title":"Cetuximab plus radio\u2010chemotherapy in locally advanced anal cancer: Interim results of the French multicenter phase II trial ACCORD16 [Abstract]","volume":"29","author":"Deutsch E","year":"2011","journal-title":"J Clin Oncol"},{"issue":"15","key":"e_1_2_7_18_1","article-title":"Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5\u2010fluorouracil (5\u2010FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV\u2010positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): Safety and preliminary efficacy results [Abstract]","volume":"30","author":"Garg M","year":"2012","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.08.030"},{"key":"e_1_2_7_20_1","first-page":"2926","article-title":"Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma","volume":"60","author":"Bruns CJ","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_7_21_1","first-page":"1459","article-title":"Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor","volume":"71","author":"Ciardiello F","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr592"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.3220"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.5669"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23062"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr524"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-5112"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.09.023"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.28045","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.28045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:14:58Z","timestamp":1760271298000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.28045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,14]]},"references-count":27,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2013,8,15]]}},"alternative-id":["10.1002\/cncr.28045"],"URL":"https:\/\/doi.org\/10.1002\/cncr.28045","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,14]]}}}